Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-1080. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 0.88 |
| ▸ | CDK7 | P50613 | 3/20 | 0.88 |
| ▸ | CDK1 | P06493 | 2/20 | 0.88 |
| ▸ | CDK2 | P24941 | 2/20 | 0.88 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.88 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.88 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.88 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.88 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.88 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.88 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.88 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.88 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.88 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.88 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.88 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.88 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1080 SCHEMBL2686165 | 0.94 | CDK7 (0.86) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL3701569 | 0.94 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL29361806 | 0.94 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL30298327 | 0.94 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL394519 | 0.94 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL29374248 | 0.94 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL395245 | 0.93 | CDK7 (0.98) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2684436 | 0.91 | CDK7 (0.91) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL27755135 | 0.91 | CDK7 (0.91) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2685991 | 0.89 | CDK7 (0.86) | CDK7CDK1CDK2DYRK3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115865-A1 | New Salts of an Indole Derivative and Their Use in Medicine | ASTRAZENECA AB (SE) | 2012-05-10 | — | — | US | claimed |
| US-20090221576-A1 | Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts | ASTRAZENECA AB GLOBAL INTELLECTUAL PROPERTY (SE) | 2009-09-03 | — | — | US | claimed |
| CN-101389623-A | New salts of an indole derivative and their use in medicine | ASTRAZENECA AB (SE) | 2009-03-18 | — | — | CN | claimed |
| EP-1981500-A1 | PHARMACEUTICAL USE OF 2-HYDROXY-3- [5-(MORPHOLIN-4-YLMETHYL) PYRIDINE-2-YL]-1H- INDOLE-5-CARBONITRILE AS A FREE BASE OR SALTS | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | claimed |
| WO-2007089192-A1 | PHARMACEUTICAL USE OF 2-HYDROXY-3- [5- (MORPHOLIN-4- YLMETHYL) PYRIDINE-2-YL] -1H- INDOLE-5-CARBONITRILE AS A FREE BASE OR SALTS | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | WO | claimed |
| US-20120115865-A1 | New Salts of an Indole Derivative and Their Use in Medicine | ASTRAZENECA AB (SE) | 2012-05-10 | — | — | US | disclosed |
| US-20090221576-A1 | Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts | ASTRAZENECA AB GLOBAL INTELLECTUAL PROPERTY (SE) | 2009-09-03 | — | — | US | disclosed |
| CN-101389623-A | New salts of an indole derivative and their use in medicine | ASTRAZENECA AB (SE) | 2009-03-18 | — | — | CN | disclosed |
| EP-1991539-A1 | NEW SALTS OF AN INDOLE DERIVATIVE AND THEIR USE IN MEDICINE | AstraZeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| EP-1981500-A1 | PHARMACEUTICAL USE OF 2-HYDROXY-3- [5-(MORPHOLIN-4-YLMETHYL) PYRIDINE-2-YL]-1H- INDOLE-5-CARBONITRILE AS A FREE BASE OR SALTS | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007100282-A1 | NEW SALTS OF AN INDOLE DERIVATIVE AND THEIR USE IN MEDICINE | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007089192-A1 | PHARMACEUTICAL USE OF 2-HYDROXY-3- [5- (MORPHOLIN-4- YLMETHYL) PYRIDINE-2-YL] -1H- INDOLE-5-CARBONITRILE AS A FREE BASE OR SALTS | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115865-A1 | New Salts of an Indole Derivative and Their Use in Medicine | GSK3B, GSK3A, GSKIP | GSK3B 1/4885CDK7 468/4885CDK1 100/4885 |
| US-20090221576-A1 | Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts | UTRN, PNN, PPIP5K2 | GSK3B 602/4885CDK7 2336/4885CDK1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.